Additionally, in this study, A + CHP was more commonly used than CHOP in patients with sALCL, a finding not unexpected due to the universal CD30 expression in this PTCL subtype and the superior outcomes reported for A + CHP versus CHOP in ECHELON-2. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.